Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects
AUTOR(ES)
Moura Filho, Jucelio Pereira, Peixoto, Raiza Luna, Martins, Livia Gomes, Melo, Sillas Duarte de, Carvalho, Ligiana Leite de, Pereira, Ana Karine F. da Trindade C., Freire, Eutilia Andrade Medeiros
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2014-01
RESUMO
Systemic Lupus Erythematosus is a chronic inflammatory disease with multifactorial etiology. Although clinical manifestations are varied, the skin is an important target-organ, which contributes to the inclusion of skin lesions in 4 out of the 17 new criteria for the diagnosis of the disease, according to the Systemic Lupus International Collaborating Clinics. The cutaneous manifestations of lupus are pleomorphic. Depending on their clinical characteristics, they can be classified into Acute Cutaneous Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus and Intermittent Cutaneous Lupus Erythematosus. Treatment is based on preventive measures, reversal of inflammation, prevention of damage to target organs and relief of adverse events due to pharmacological therapy. The most commonly used treatment options are topical, systemic and surgical treatment, as well as phototherapy. The correct handling of the cases depends on a careful evaluation of the morphology of the lesions and the patient's general status, always taking into consideration not only the benefits but also the side effects of each therapeutic proposal.
Documentos Relacionados
- Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features.
- Attributing psychopathology to systemic lupus erythematosus: some methodological considerations.
- Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations.
- Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations.
- Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update